Methods and compounds for prevention of graft rejection
AssigneeThe Beth Israel Hospital Association
InventorsTerry Strom, Towia Libermann
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.
Claims1
A method of inhibiting the rejection of an islet cell transplanted into a human patient, the method comprising:
- (a) introducing into an islet cell, ex vivo, a nucleic acid sequence encoding CTLA4-Ig operably linked to a promotor, wherein the CTLA4-Ig is expressed by the islet cell, and
- (b) transplanting the islet cell into the patient, wherein CTLA4-Ig is expressed at al level sufficient to inhibit the rejection of the transplanted cell.
Dependencies are inferred from the claim text.